Boston Trust Walden Corp Purchases New Shares in Merit Medical Systems, Inc. $MMSI

Boston Trust Walden Corp acquired a new position in Merit Medical Systems, Inc. (NASDAQ:MMSI) during the first quarter, Holdings Channel.com reports. The firm acquired 277,209 shares of the medical instruments supplier’s stock, valued at approximately $19,108,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC purchased a new stake in shares of Merit Medical Systems during the fourth quarter worth about $25,000. Maseco LLP purchased a new stake in Merit Medical Systems during the 4th quarter worth approximately $26,000. Torren Management LLC acquired a new position in shares of Merit Medical Systems in the 4th quarter valued at approximately $38,000. Covestor Ltd raised its position in shares of Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 336 shares in the last quarter. Finally, Danske Bank A S purchased a new position in shares of Merit Medical Systems during the 3rd quarter valued at approximately $42,000. 99.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on MMSI. Canaccord Genuity Group dropped their price target on shares of Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Barrington Research cut their target price on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a research note on Monday, April 20th. Weiss Ratings cut shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Citigroup reiterated an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Finally, Wall Street Zen lowered Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $92.80.

Merit Medical Systems Price Performance

NASDAQ:MMSI opened at $71.09 on Friday. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45. The stock has a 50 day moving average of $65.44 and a 200-day moving average of $73.65. The firm has a market capitalization of $4.24 billion, a PE ratio of 30.78, a price-to-earnings-growth ratio of 2.21 and a beta of 0.52. Merit Medical Systems, Inc. has a 52 week low of $59.74 and a 52 week high of $96.74.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.10. The business had revenue of $381.88 million during the quarter, compared to analyst estimates of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.86 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Analysts predict that Merit Medical Systems, Inc. will post 3.62 EPS for the current year.

Insider Activity

In other news, insider Brian G. Lloyd purchased 2,000 shares of the stock in a transaction dated Thursday, May 7th. The stock was acquired at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the transaction, the insider owned 2,000 shares of the company’s stock, valued at approximately $125,240. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the sale, the director owned 7,809 shares in the company, valued at approximately $488,921.49. This represents a 39.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.70% of the stock is currently owned by corporate insiders.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.